Literature DB >> 2910700

[Retard morphine in the long-term therapy of severe tumor pain].

M Zenz1, M Strumpf, M Tryba, E Röhrs, B Steffmann.   

Abstract

35 patients with severe cancer pain received oral retard morphine. Pain reduction was achieved in each case; duration of effectiveness was between 8 and 12 hours. Mean daily dose was 230 mg morphine, but in individual cases the maximal daily dose had to be over 800 mg. The Karnofsky index of physical capacity was increased in all patients. The main side effect was constipation, which actually increased in the course of treatment. On the other hand, nausea and vomiting decreased after a few weeks. No dependence developed in any of the patients. This form of morphine medication thus was effective over long periods and it has become an important part in the range of strongly effective analgesics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910700     DOI: 10.1055/s-2008-1066549

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  12 in total

1.  [Prescription of strong opioids by physicians.].

Authors:  J Sorge; M Zenz
Journal:  Schmerz       Date:  1990-09       Impact factor: 1.107

2.  [Not Available].

Authors:  H Goeke; M Herbst
Journal:  Schmerz       Date:  1995-11       Impact factor: 1.107

3.  [The estimation of the i.m. morphine-equivalent in cancer pain treatment with different opioids or different routes of administrations. Practical meaning and limitations.].

Authors:  J Jage; R K Portenoy; K M Foley
Journal:  Schmerz       Date:  1990-06       Impact factor: 1.107

4.  [Oral opioids in patients with non-malignant pain.].

Authors:  M Zenz; M Strumpf; A Willweber-Strumpf
Journal:  Schmerz       Date:  1990-03       Impact factor: 1.107

5.  Attitudes of Swiss physicians in prescribing opiates for cancer pain.

Authors:  F Stiefel; R Morant; A Radziwill; H J Senn
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

6.  [Not Available].

Authors:  M Zenz
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

7.  [Opioids in "non-malignant" pain-results of long-term treatment in patients with rheumatic disease.].

Authors:  J Sorge; B Steffmann; C Lehmkuhl; I Pichlmayr
Journal:  Schmerz       Date:  1991-06       Impact factor: 1.107

8.  [Intractable cancer pain as a reason for referral : Analysis of pain etiology and previous drug treatment.].

Authors:  S Grond; D Zech; H Dahlmann; S A Schug; B Stobbe; K A Lehmann
Journal:  Schmerz       Date:  1990-12       Impact factor: 1.107

9.  [Pain relief in the final stage of cancer.].

Authors:  S Grond; D Zech; G Horrichs-Haermeyer; K A Lehmann
Journal:  Schmerz       Date:  1990-03       Impact factor: 1.107

10.  [Slow-release morphine liquid suspension for the therapy of cancer pain and non-cancer pain-A pilot study.].

Authors:  M Strumpf; B Donner; M Zenz
Journal:  Schmerz       Date:  1995-05       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.